Registration statement for securities issued by foreign private issuers in certain business combination transactions

Consolidated Statement of Cash Flows

v3.22.1
Consolidated Statement of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities          
Loss for the period $ (91,357) $ (10,847) $ (374,511) $ (188,030) $ (140,287)
Adjustments to reconcile Loss for the period to net cash (used in) provided by operating activities:          
Recapitalization transaction expense     148,722    
Share-based compensation 8,402 2,802 46,307 9,557 7,966
Depreciation and amortization 9,458 5,848 35,004 14,487 2,496
Change in fair value of warrant liabilities (5,575)   (27,811)    
Gain on remeasurement of equity interest     (10,495)    
Finance costs 6,628 992 14,291 4,530 1,116
Gain on sale of subsidiary   (3,917) (3,917)    
Share of loss of equity-accounted investees   455 2,602 1,124  
Taxation 9 8 (1,474) 4,639 (5,559)
Impairment expense     941 6,436  
Exchange loss 447 573 (868) 2,836 (17,075)
Finance income (255) (14) (326) (610) (1,015)
Cash flows from (used in) operations before changes in working capital (72,243) (4,100) (171,535) (145,031) (152,358)
Working capital adjustments          
(Increase) / Decrease in trade and other receivables 126 (8,704) (21,829) 738 (9,308)
Increase / (Decrease) in trade and other payables 3,160 34,304 47,496 2,323 18,052
(Increase) / Decrease in assets held for sale       (3,282)  
Increase / (Decrease) liabilities directly associated with the assets held for sale       1,822  
Net cash (used in) provided by operating activities (68,957) 21,500 (145,868) (143,430) (143,614)
Cash flows from investing activities          
Development costs capitalized (9,298) (7,198) (32,120) (36,509) (36,036)
Acquisitions, net of cash acquired     (13,798) (25,671)  
Capital expenditures (2,613) (311) (8,103) (719) (1,915)
Purchase of shares in associates and joint ventures   (2,000) (5,000) (10,000)  
Cash assumed upon consolidation through control     3,792    
Proceeds from sale of investment in subsidiary   2,213 2,213    
Payment of lease deposit     (2,105)    
Interest received 255 14 326 673 1,015
Net cash used in investing activities (11,656) (7,282) (54,795) (72,226) (36,936)
Cash flows from financing activities          
Proceeds from issuance of notes and warrants 100,000   270,563    
Repayment of cash loan     (82,000)   (1,231)
Payment of equity and debt issuance costs (5,002)   (36,043) (10,245) (773)
Repayments of borrowings     (7,431)    
Principal payments on leases (460) (1,520) (4,156) (1,541) (1,228)
Interest paid (22) (18) (5,219) (252) (851)
Payments to acquire non-controlling interests     (2,352)    
Proceeds from issuance of convertible loan notes       100,000 51,064
Repayment of convertible loan notes         (14,794)
Other financing activities, net (1,538) (482) (470)    
Net cash provided by (used in) financing activities 92,978 (2,020) 362,203 100,058 352,521
Net increase in cash and cash equivalents 12,365 12,198 161,540 (115,598) 171,971
Cash and cash equivalents at January 1, 262,581 101,757 101,757 214,888 46,031
Effect of movements in exchange rate on cash held 32 (57) (716) 2,467 (3,114)
Cash and cash equivalents at March 31, 274,978 113,898 262,581 101,757 $ 214,888
Non-cash financing and investing activities:          
Acquisition date fair value of Higi upon consolidation     86,043    
Conversion of borrowings     70,000    
Acquisitions of non-controlling interests     (54,662)    
Fair value of warrants issued in Merger     (31,009)    
Fair value of warrants issued in connection with Loans and borrowings 3,418   (16,930)    
Equity and debt issuance costs in accruals and provisions     (4,521)    
Equity issued as consideration for acquisitions     (2,349)    
Share-based compensation expense capitalized in development costs $ (772) $ (380) $ (1,879) $ (7,616)